Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.

Autor: Nagle CM; Gynaecological Cancers Group, Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Ibiebele TI; Gynaecological Cancers Group, Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Bandera EV; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA., Cramer D; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA., Doherty JA; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA., Giles GG; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia., Goodman MT; Cancer Prevention and Control Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Hanley GE; University of British Columbia, Department of Obstetrics & Gynaecology, Vancouver, BC, Canada., Harris HR; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA., Jensen A; Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark., Kjaer SK; Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark.; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Lee AW; Department of Public Health, California State University, Fullerton, Fullerton, CA, USA., Milne RL; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia., Qin B; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA., Richardson J; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Sasamoto N; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Sieh W; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Terry KL; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA., Titus L; Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA., Trabert B; Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.; Department of Obstetrics and Gynecology, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA., Wentzensen N; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA., Wu AH; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Berchuck A; Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC, USA., Pike M; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pearce CL; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA., Webb PM; Gynaecological Cancers Group, Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. penny.webb@qimrberghofer.edu.au.; University of Queensland, School of Public Health, Brisbane, QLD, Australia. penny.webb@qimrberghofer.edu.au.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2024 Oct; Vol. 131 (6), pp. 1043-1049. Date of Electronic Publication: 2024 Jul 18.
DOI: 10.1038/s41416-024-02792-7
Abstrakt: Background: Tea and coffee are the most frequently consumed beverages in the world. Green tea in particular contains compounds with potential anti-cancer effects, but its association with survival after ovarian cancer is uncertain.
Methods: We investigated the associations between tea and coffee consumption before diagnosis and survival using data from 10 studies in the Ovarian Cancer Association Consortium. Data on tea (green, black, herbal), coffee and caffeine intake were available for up to 5724 women. We used Cox proportional hazards regression to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI).
Results: Compared with women who did not drink any green tea, consumption of one or more cups/day was associated with better overall survival (aHR = 0.84, 95% CI 0.71-1.00, p-trend = 0.04). A similar association was seen for ovarian cancer-specific survival in five studies with this information (aHR = 0.81, 0.66-0.99, p-trend = 0.045). There was no consistent variation between subgroups defined by clinical or lifestyle characteristics and adjustment for other aspects of lifestyle did not appreciably alter the estimates. We found no evidence of an association between coffee, black or herbal tea, or caffeine intake and survival.
Conclusion: The observed association with green tea consumption before diagnosis raises the possibility that consumption after diagnosis might improve patient outcomes.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: